Sanofi-Synthelabo Xaliproden ALS Trial Analysis Begins
Executive Summary
Two Phase III trials of xaliproden for treatment of amylotrophic lateral sclerosis have been completed and are being analyzed, Sanofi-Synthelabo Exec VP-Scientific Affairs Gerard Le Fur announced at an analysts briefing in London Feb. 23.
You may also be interested in...
Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III
Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.
Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III
Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.
Bristol/Sanofi Plavix Sales Triple In U.S.; Avapro Doubles
Sanofi-Synthelabo is planning an aggressive clinical trial program to expand labeling for its pair of cardiovascular products co-promoted with Bristol-Myers Squibb in the U.S., Plavix and Avapro.